|
1
|
Kebebew E, Reiff E, Duh QY, Clark OH and
McMillan A: Extent of disease at presentation and outcome for
adrenocortical carcinoma: Have we made progress? World J Surg.
30:872–878. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kerkhofs TM, Verhoeven RH, Van der Zwan
JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV and
Haak HR: Adrenocortical carcinoma: A population-based study on
incidence and survival in the Netherlands since 1993. Eur J Cancer.
49:2579–2586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sharma E and Dahal S, Sharma P, Bhandari
A, Gupta V, Amgai B and Dahal S: The characteristics and trends in
adrenocortical carcinoma: A united states population based study. J
Clin Med Res. 10:636–640. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bourdeau I, MacKenzie-Feder J and Lacroix
A: Recent advances in adrenocortical carcinoma in adults. Curr Opin
Endocrinol Diabetes Obes. 20:192–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wandoloski M, Bussey KJ and Demeure MJ:
Adrenocortical cancer. Surg Clin North Am. 89:1255–1267. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Else T, Kim AC, Sabolch A, Raymond VM,
Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ and Hammer
GD: Adrenocortical carcinoma. Endocr Rev. 35:282–326. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grubbs EG, Callender GG, Xing Y, Perrier
ND, Evans DB, Phan AT and Lee JE: Recurrence of adrenal cortical
carcinoma following resection: Surgery alone can achieve results
equal to surgery plus mitotane. Ann Surg Oncol. 17:263–270. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Postlewait LM, Ethun CG, Tran TB, Prescott
JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, et
al: Outcomes of adjuvant mitotane after resection of adrenocortical
carcinoma: A 13-institution study by the us adrenocortical
carcinoma group. J Am Coll Surg. 222:480–490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stephan EA, Chung TH, Grant CS, Kim S, Von
Hoff DD, Trent JM and Demeure MJ: Adrenocortical carcinoma survival
rates correlated to genomic copy number variants. Mol Cancer Ther.
7:425–431. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lam AK: Update on adrenal tumours in 2017
world health organization (WHO) of endocrine tumours. Endocr
Pathol. 28:213–227. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Erickson LA: Challenges in surgical
pathology of adrenocortical tumours. Histopathology. 72:82–96.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papotti M, Libè R, Duregon E, Volante M,
Bertherat J and Tissier F: The weiss score and
beyond-histopathology for adrenocortical carcinoma. Horm Cancer.
2:333–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giordano TJ, Kuick R, Else T, Gauger PG,
Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G and Hammer
G: Molecular classification and prognostication of adrenocortical
tumors by transcriptome profiling. Clin Cancer Res. 15:668–676.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kulshrestha A and Suman S: Common module
analysis reveals prospective targets and mechanisms of pediatric
adrenocortical adenoma and carcinoma. Oncol Lett. 15:3267–3272.
2018.PubMed/NCBI
|
|
15
|
Yuan L, Qian G, Chen L, Wu CL, Dan HC,
Xiao Y and Wang X: Co-expression network analysis of biomarkers for
adrenocortical carcinoma. Front Genet. 9:3282018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kulshrestha A, Suman S and Ranjan R:
Network analysis reveals potential markers for pediatric
adrenocortical carcinoma. OncoTargets Ther. 9:4569–4581. 2016.
View Article : Google Scholar
|
|
17
|
Duregon E, Rapa I, Votta A, Giorcelli J,
Daffara F, Terzolo M, Scagliotti GV, Volante M and Papotti M:
MicroRNA expression patterns in adrenocortical carcinoma variants
and clinical pathologic correlations. Hum Pathol. 45:1555–1562.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Soon PS, Gill AJ, Benn DE, Clarkson A,
Robinson BG, McDonald KL and Sidhu SB: Microarray gene expression
and immunohistochemistry analyses of adrenocortical tumors identify
IGF2 and Ki-67 as useful in differentiating carcinomas from
adenomas. Endocr Relat Cancer. 16:573–583. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Demeure MJ, Coan KE, Grant CS, Komorowski
RA, Stephan E, Sinari S, Mount D and Bussey KJ: PTTG1
overexpression in adrenocortical cancer is associated with poor
survival and represents a potential therapeutic target. Surgery.
154:1405–1416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Clough E and Barrett T: The gene
expression omnibus database. Methods Mol Biol. 1418:93–110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res 41 (Database Issue).
D991–D995. 2013.
|
|
22
|
Li L, Lei Q, Zhang S, Kong L and Qin B:
Screening and identification of key biomarkers in hepatocellular
carcinoma: Evidence from bioinformatic analysis. Oncol Rep.
38:2607–2618. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang DW, Sherman BT, Tan Q, Collins JR,
Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki
RA: The DAVID gene functional classification tool: A novel
biological module-centric algorithm to functionally analyze large
gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanehisa M: The KEGG database. Novartis
Found Symp. 247:91–103, 119-128, 244–252. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alshabi AM, Vastrad B, Shaikh IA and
Vastrad C: Identification of important invasion and proliferation
related genes in adrenocortical carcinoma. Med Oncol. 36:732019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia WX, Yu Q, Li GH, Liu YW, Xiao FH, Yang
LQ, Rahman ZU, Wang HT and Kong QP: Identification of four hub
genes associated with adrenocortical carcinoma progression by
WGCNA. PEERJ. 7:e65552019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bandettini WP, Kellman P, Mancini C,
Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and
Arai AE: Multicontrast delayed enhancement (MCODE) improves
detection of subendocardial myocardial infarction by late
gadolinium enhancement cardiovascular magnetic resonance: A
clinical validation study. J Cardiovasc Magn Reson. 14:832012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang AM, Song H, Shen YH and Liu Y:
Construction of a gene-gene interaction network with a combined
score across multiple approaches. Genet Mol Res. 14:7018–7030.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goldman M, Craft B, Swatloski T, Cline M,
Morozova O, Diekhans M, Haussler D and Zhu J: The UCSC cancer
genomics browser: Update 2015. Nucleic Acids Res. 43:D812–D817.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Giordano TJ, Thomas DG, Kuick R, Lizyness
M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson
NW, et al: Distinct transcriptional profiles of adrenocortical
tumors uncovered by DNA microarray analysis. Am J Pathol.
162:521–531. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Altieri B, Colao A and Faggiano A: The
role of insulin-like growth factor system in the adrenocortical
tumors. Minerva Endocrinol. 44:43–57. 2019.PubMed/NCBI
|
|
36
|
Gaujoux S, Grabar S, Fassnacht M, Ragazzon
B, Launay P, Libé R, Chokri I, Audebourg A, Royer B, Sbiera S, et
al: β-catenin activation is associated with specific clinical and
pathologic characteristics and a poor outcome in adrenocortical
carcinoma. Clin Cancer Res. 17:328–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dworakowska D, Drabarek A, Wenzel I,
Babińska A, Świątkowska-Stodulska R and Sworczak K: Adrenocortical
cancer (ACC)-literature overview and own experience. Endokrynol
Pol. 65:492–502. 2014.PubMed/NCBI
|
|
38
|
Varghese J and Habra MA: Update on
adrenocortical carcinoma management and future directions. Curr
Opin Endocrinol Diabetes Obes. 24:208–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Borges KS, Moreno DA, Martinelli CE Jr,
Antonini SR, de Castro M, Tucci S Jr, Neder L, Ramalho LN,
Seidinger AL, Cardinalli I, et al: Spindle assembly checkpoint gene
expression in childhood adrenocortical tumors (ACT): Overexpression
of aurora kinases A and B is associated with a poor prognosis.
Pediatr Blood Cancer. 60:1809–1816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Damodaran AP, Vaufrey L, Gavard O and
Prigent C: Aurora a kinase is a priority pharmaceutical target for
the treatment of cancers. Trends Pharmacol Sci. 38:687–700. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ye C, Wang J, Wu P, Li X and Chai Y:
Prognostic role of cyclin B1 in solid tumors: A meta-analysis.
Oncotarget. 8:2224–2232. 2017.PubMed/NCBI
|
|
42
|
Terrano DT, Upreti M and Chambers TC:
Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation
acts as a functional link coupling mitotic arrest and apoptosis.
Mol Cell Biol. 30:640–656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Glover AR, Zhao JT, Gill AJ, Weiss J,
Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, et al:
MicroRNA-7 as a tumor suppressor and novel therapeutic for
adrenocortical carcinoma. Oncotarget. 6:36675–36688. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nilubol N, Boufraqech M, Zhang L, Gaskins
K, Shen M, Zhang YQ, Gara SK, Austin CP and Kebebew E: Synergistic
combination of flavopiridol and carfilzomib targets commonly
dysregulated pathways in adrenocortical carcinoma and has
biomarkers of response. Oncotarget. 9:33030–33042. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ip JC, Pang TC, Glover AR, Soon P, Zhao
JT, Clarke S, Robinson BG, Gill AJ and Sidhu SB:
Immunohistochemical validation of overexpressed genes identified by
global expression microarrays in adrenocortical carcinoma reveals
potential predictive and prognostic biomarkers. Oncologist.
20:247–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Drelon C, Berthon A, Mathieu M, Ragazzon
B, Kuick R, Tabbal H, Septier A, Rodriguez S, Batisse-Lignier M,
Sahut-Barnola I, et al: EZH2 is overexpressed in adrenocortical
carcinoma and is associated with disease progression. Hum Mol
Genet. 25:2789–2800. 2016.PubMed/NCBI
|
|
47
|
Kotoula V, Krikelis D, Karavasilis V,
Koletsa T, Eleftheraki AG, Televantou D, Christodoulou C, Dimoudis
S, Korantzis I, Pectasides D, et al: Expression of DNA repair and
replication genes in non-small cell lung cancer (NSCLC): A role for
thymidylate synthetase (TYMS). BMC Cancer. 12:3422012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Formentini A, Henne-Bruns D and Kornmann
M: Thymidylate synthase expression and prognosis of patients with
gastrointestinal cancers receiving adjuvant chemotherapy: A review.
Langenbecks Arch Surg. 389:405–413. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
A systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang YC, Wu GC, Jin L, Wang KL, Bai ZG,
Wang J and Zhang ZT: Association of thymidylate synthase
polymorphisms with the tumor response to preoperative
chemoradiotherapy in rectal cancer: A systematic review and
meta-analysis. Pharmacogenomics J. 17:265–273. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mizutani Y, Wada H, Yoshida O, Fukushima
M, Nonomura M, Nakao M and Miki T: Significance of thymidylate
synthase activity in renal cell carcinoma. Clin Cancer Res.
9:1453–1460. 2003.PubMed/NCBI
|
|
52
|
Burdelski C, Strauss C, Tsourlakis MC,
Kluth M, Hube-Magg C, Melling N, Lebok P, Minner S, Koop C, Graefen
M, et al: Overexpression of thymidylate synthase (TYMS) is
associated with aggressive tumor features and early PSA recurrence
in prostate cancer. Oncotarget. 6:8377–8387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Grolmusz VK, Karászi K, Micsik T, Tóth EA,
Mészáros K, Karvaly G, Barna G, Szabó PM, Baghy K, Matkó J, et al:
Cell cycle dependent RRM2 may serve as proliferation marker and
pharmaceutical target in adrenocortical cancer. Am J Cancer Res.
6:2041–2053. 2016.PubMed/NCBI
|
|
54
|
Wang N, Zhan T, Ke T, Huang X, Ke D, Wang
Q and Li H: Increased expression of RRM2 by human papillomavirus E7
oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer.
110:1034–1044. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ying H, Xu Z, Chen M, Zhou S, Liang X and
Cai X: Overexpression of Zwint predicts poor prognosis and promotes
the proliferation of hepatocellular carcinoma by regulating
cell-cycle-related proteins. Onco Targets Ther. 11:689–702. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Woo Seo D, Yeop You S, Chung WJ, Cho DH,
Kim JS and Su Oh J: Zwint-1 is required for spindle assembly
checkpoint function and kinetochore-microtubule attachment during
oocyte meiosis. Sci Rep. 5:154312015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cottineau J, Kottemann MC, Lach FP, Kang
YH, Vély F, Deenick EK, Lazarov T, Gineau L, Wang Y, Farina A, et
al: Inherited GINS1 deficiency underlies growth retardation along
with neutropenia and NK cell deficiency. J Clin Invest.
127:1991–2006. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nakahara I, Miyamoto M, Shibata T,
Akashi-Tanaka S, Kinoshita T, Mogushi K, Oda K, Ueno M, Takakura N,
Mizushima H, et al: Up-regulation of PSF1 promotes the growth of
breast cancer cells. Genes Cells. 15:1015–1024. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tahara H, Naito H, Kise K, Wakabayashi T,
Kamoi K, Okihara K, Yanagisawa A, Nakai Y, Nonomura N, Morii E, et
al: Evaluation of PSF1 as a prognostic biomarker for prostate
cancer. Prostate Cancer Prostatic Dis. 18:56–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang J, Wu Q, Wang Z, Zhang Y, Zhang G,
Fu J and Liu C: Knockdown of PSF1 expression inhibits cell
proliferation in lung cancer cells in vitro. Tumour Biol.
36:2163–2168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhou L, Sun XJ, Liu C, Wu QF, Tai MH, Wei
JC, Lei L, Meng FD, Qu K and Xu J: Overexpression of PSF1 is
correlated with poor prognosis in hepatocellular carcinoma
patients. Int J Biol Markers. 30:e56–e64. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhou B, Yuan T, Liu M, Liu H, Xie J, Shen
Y and Chen P: Overexpression of the structural maintenance of
chromosome 4 protein is associated with tumor de-differentiation,
advanced stage and vascular invasion of primary liver cancer. Oncol
Rep. 28:1263–1268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Feng XD, Song Q, Li CW, Chen J, Tang HM,
Peng ZH and Wang XC: Structural maintenance of chromosomes 4 is a
predictor of survival and a novel therapeutic target in colorectal
cancer. Asian Pac J Cancer Prev. 15:9459–9465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu W, Liang B, Liu H, Huang Y, Yin X,
Zhou F, Yu X, Feng Q, Li E, Zou Z and Wu L: Overexpression of
non-SMC condensin I complex subunit G serves as a promising
prognostic marker and therapeutic target for hepatocellular
carcinoma. Int J Mol Med. 40:731–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
